<DOC>
	<DOCNO>NCT01335958</DOCNO>
	<brief_summary>This Phase I , multi-center , open-label , dose-escalation study DMUC5754A administer single agent intravenous ( IV ) infusion patient platinum-resistant ovarian cancer unresectable pancreatic cancer .</brief_summary>
	<brief_title>Safety Pharmacokinetics DMUC5754A Administered Intravenously Patients With Platinum-Resistant Ovarian Cancer Unresectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Life expectancy least 12 week Documented willingness use effective mean contraception woman childbearing potential Measurable disease least one lesion accurately measure least one dimension Inclusion Criteria Specific Patients Ovarian Cancer : Advanced , epithelial ovarian , primary peritoneal , fallopian tube cancer progress relapse within 6 month recent treatment platinumcontaining chemotherapy regimen , standard therapy exists For patient doseexpansion cohort study , two prior chemotherapy regimens treatment platinumresistant ovarian cancer Inclusion Criteria Specific Patients Pancreatic Cancer : Incurable , locally advanced , metastatic disease standard therapy exist , consist unresectable pancreatic ductal adenocarcinoma , include recurrence previouslyresected disease consider unresectable curative intent No one chemotherapy regimen ( approved experimental ) administer metastatic setting Antitumor therapy , include chemotherapy , biologic , experimental , hormonal therapy within 4 week prior Day 1 Palliative radiation bone metastasis within 2 week prior Day 1 Major surgical procedure within 4 week prior Day 1 Known active bacterial , viral , fungal , mycobacterial , infection ( include HIV atypical mycobacterial disease , exclude fungal infection nail bed ) Current Grade &gt; 1 toxicity ( except alopecia anorexia ) prior therapy Grade &gt; 1 neuropathy cause History severe allergic anaphylactic reaction monoclonal antibody therapy ( recombinant antibodyrelated fusion protein ) Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Untreated active central nervous system ( CNS ) metastases ( progress require anticonvulsant corticosteroid symptomatic control ) . Patients history treat CNS metastasis eligible , provide meet follow criterion : evaluable measurable disease outside CNS , radiographic demonstration improvement upon completion CNSdirected therapy evidence interim progression completion CNSdirected therapy screen radiographic study , screen CNS radiographic study &gt; = 8 week since completion radiotherapy &gt; = 4 week since discontinuation corticosteroid anticonvulsant . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Evidence significant uncontrolled concomitant disease , cardiovascular disease ( include stroke , New York Heart Association Class III IV cardiac disease myocardial infarction within 6 month prior screen , unstable arrhythmia , unstable angina ) ; nervous system , pulmonary ( include obstructive pulmonary disease history symptomatic bronchospasm ) , renal , hepatic , endocrine , gastrointestinal disorder ; serious nonhealing wound fracture Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>